| Keywords: |
clinical feature; united states; prevalence; history, 21st century; history, 20th century; blood bank; blood banks; antivirus agent; acquired immune deficiency syndrome; acquired immunodeficiency syndrome; immunomodulating agent; antiretroviral therapy, highly active; proteinase inhibitor; anti-hiv agents; financing, government; sexual behavior; hiv; disease transmission; epidemic; opportunistic infection; zidovudine; world health; methisoprinol; rna directed dna polymerase inhibitor; saquinavir; aids vaccines; didanosine; efavirenz; research support; humans; human; male; female; priority journal; article; zalcitabine; imreg 1; hiv seroprevalence
|
